Johnson & Johnson Reports Encouraging First-in-Human Data for Erda-iDRS (formerly TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients…
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology…
Planet DDS 2026 Dental Outlook Shows More New Patients, Fewer No-Shows Across the Industry Planet DDS, a leading provider of cloud-based, enterprise-grade dental software solutions, announced the release of its 2026 Dental Industry Outlook, an annual benchmark report designed to help…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C GeneDx the leader in rare disease diagnosis and improving health through the power of genomic data, announced a new genetic testing program…
Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide…
AbbVie reports positive topline results from a Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog evaluated in adults. AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for weight management and metabolic health, reinforces its position as a…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to…
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced U.S. Food and Drug Administration…
MED-EL U.S. Launches Two New Rechargeable Battery Options with up to 23 Hours of Hearing for the SONNET 3 Audio Processor MED-EL U.S. announced today two new rechargeable battery options: the Standard Pro and the Micro Pro. The new options…
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery.…